24/7 Market News Snapshot 14 January, 2025 – Eterna Therapeutics Inc. Common Stock (NASDAQ:ERNA)

January 14, 2025

DENVER, Colo., 14 January, 2025 (247marketnews.com) – (NASDAQ:ERNA) are discussed in this article.
Eterna Therapeutics Inc. (NASDAQ:ERNA) is making headlines with a significant turnaround, as its stock price has surged dramatically today. Opening at $0.51, ERNA has skyrocketed to $0.744, reflecting an astonishing increase of 140.78% from yesterday’s closing price of $0.309. This surge signals a heightened enthusiasm from investors, with trading volumes reaching 354.17 million shares, indicating strong market interest and confidence in the company’s future prospects.

The optimism surrounding Eterna comes on the heels of promising preclinical results for its lead cell therapy, ERNA-101, which is designed to combat advanced ovarian cancer. The therapy aims to harness the body’s immune system to target tumors more effectively. In a compelling proof-of-concept study, significant T cell infiltration and a substantial reduction in tumor burden were observed in ovarian cancer mouse models following a single dose of ERNA-101. Furthermore, these models exhibited prolonged survival rates compared to control groups, marking a significant advancement in potential treatment options.

Sanjeev Luther, CEO of Eterna Therapeutics, expressed his enthusiasm for the findings, stating that they represent a watershed moment for both ERNA-101 and the company. He emphasized the innovative capacity of the cell therapy to potentially revolutionize the treatment landscape for solid tumors, specifically benefiting patients battling ovarian cancer. The collaboration with MD Anderson has been pivotal in achieving these results, and Eterna is committed to furthering its research agenda.

ERNA-101 utilizes induced pluripotent stem cells to create allogeneic mesenchymal stem cells that secrete interleukins IL-7 and IL-15, cytokines that are crucial for enhancing immune responses. By converting “cold” tumor microenvironments into “hot” ones, ERNA-101 seeks to bolster the effectiveness of existing therapies, including CAR-T and CAR-NK cell treatments. Eterna Therapeutics continues to explore the clinical potential of ERNA-101 as part of its mission to deliver innovative solutions for patients in need.

Related news for (ERNA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.